Table 1.
Demographic characteristics of participants (total vaccinated cohort)
| ZOE-50 Asian population ≥50 YOA |
Pooled ZOE-50/70 Asian population ≥70 YOA |
|||
|---|---|---|---|---|
| RZV (N = 1432) | Placebo (N = 1434) | RZV (N = 1471) | Placebo (N = 1472) | |
| Number of participants, n (%) | ||||
| Hong Kong | 236 (16.5) | 234 (16.3) | 126 (8.6) | 123 (8.4) |
| Japan | 288 (20.1) | 289 (20.2) | 322 (21.9) | 322 (21.9) |
| South Korea | 268 (18.7) | 271 (18.9) | 331 (22.5) | 335 (22.7) |
| Taiwan | 640 (44.7) | 640 (44.6) | 692 (47.0) | 692 (47.0) |
| Age at dose 1 (years±SD) | 62.0 ± 9.1 | 62.0 ± 9.0 | 75.9 ± 4.7 | 76.0 ± 4.7 |
| Female, n (%) | 880 (61.5) | 863 (60.2) | 740 (50.3) | 768 (52.2) |
RZV, participants receiving the adjuvanted recombinant zoster vaccine; Placebo, participants receiving placebo; YOA, years of age; N, total number of participants; n (%), number (percentage) of participants in each category; SD, standard deviation